Acesion Pharma raises 9.1 million EUR in first closing of new funding from Novo Seeds and Wellcome Trust
Acesion Pharma, a Danish biotech company developing novel treatments for atrial fibrillation (AF), today announced that it has raised 9.1 million EUR (10 million USD)in a first closing of a new investment round. The round includes current investors Wellcome Trust Ltd. and Novo Seeds, the early stage investment arm of Novo A/S. Wellcome Trust grants its funding in the form of a Translational Award and thereby continues on the Seeding Drug Discovery Initiative Award that it granted to Acesion in 2013.
Read the full press realease from Acesion Pharma.